Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev ET
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 1
Subject Area: Dental Medicine - Oral and Maxillofacial surgery
DOI: 10.5272/jimab.2017231.1483
Published online: 14 March 2017

Case Report

J of IMAB 2017 Jan-Mar;23(1):1483-1486
Milena Petkova1ORCID logoCorresponding Autor, Pavel Stanimirov1, 2ORCID logo,
1) Department of Oral and Maxillofacial surgery, Faculty of Dental medicine, Medical University Sofia, Bulgaria.
2) Department of Maxillofacial Surgery, University hospital Aleksandrovska, Sofia, Bulgaria.

Bisphosphonates are potent and effective drugs frequently used to prevent the skeletal complications associated with postmenopausal osteoporosis in women, to manage patients with multiple myeloma, hypercalcemia, and metastasis of cancer to the bone.
The search for new medications with the same therapeutic effectiveness as the bisphosphonates but fewer side effects has resulted in the discovery of Denosumab, a human monoclonal antibody against the receptor activator for nuclear factor kappa B ligand (RANKL), therefore inhibiting osteoclast differentiation and function. Denosumab is a class of drugs that are entirely different from the traditional antiresorptive drugs, the bisphosphonates. Denosumab has several advantages, including better tolerability, ease of subcutaneous injection, a shorter half-life, and a reduced incidence of nephrotoxicity.
Patients receiving bisphosphonates are at risk to develop a severe devastating complication - osteonecrosis of the jaws (ONJ) - which is challenging to treat.
Since 2010 there have been reports of ONJ in patients taking denosumab.
In the 2014 position paper of the American Association of Oral and Maxillofacial Surgeons, the nomenclature “bisphosphonate-related osteonecrosis of the jaw” was changed to “medication related osteonecrosis of the jaw” (MRONJ). The change is justified to accommodate the growing number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies.
Here we report a development of denosumab-related osteonecrosis of the jaw (DRONJ) - a new type of bony necrosis- in patient with bone metastases of breast cancer on Denosumab therapy. The patient has no previous history of taking bisphosphonates.

Key words: Denosumab, osteonecrosis, Denosumab-related osteonecrosis of the jaws,

- Download FULL TEXT /PDF 646 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Petkova M, Stanimirov P. Denosumab-related osteonecrosis of the jaws: a case report. J of IMAB. 2017 Jan-Mar;23(1):1483-1486. DOI: 10.5272/jimab.2017231.1483.

For correspondence: Milena Petkova, Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Medical University- Sofia; 1, St. Georgi Sofiiski str., 1431 Sofia, Bulgaria; E-mail:

1. Gomez-Veiga F, Ponce-Reixa J, Martinez-Breijo S, Planas J, Morote J. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas Urol Esp. 2013 May;37(5):292-304. [PubMed] [CrossRef]
2. You Tm, Lee KH, Lee SH, Park W.Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Nov;120(5):548-53. [PubMed]
3. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-676. [PubMed]
4. Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P, et al. Osteonecrosis of the jaw – prevention and treatment strategies for oral health professionals. Oral Oncology. 2013 Sept;49(9):878–86. [PubMed]
5. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. [PubMed]
6. Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansenf H et al. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg. 2014 Apr;52(4):308–13. [PubMed]
7. Neuprez A, Coste S, Rompen E, Crielaard JM, Reginster JY. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int. 2014 Jan;25(1):393–5. [PubMed]
8. O’Halloran M, Boyd NM, Smith A. Denosumab and osteonecrosis of the jaws – the pharmacology, pathogenesis and a report of two cases. Aust Dent J. 2014 Dec;59(4):516-9. [PubMed].

Received: 19 October 2016
Published online: 14 March 2017

back to Online Journal